



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/500,207

01/04/2005

Tadafumi Tamura

BJS-4093-6

7702

23117 7590 12/22/2008
NIXON & VANDERHYE, PC
901 NORTH GLEBE ROAD, 11TH FLOOR
ARLINGTON, VA 22203

EXAMINER

WEN, SHARON X

ART UNIT

PAPER NUMBER

1644

MAIL DATE

DELIVERY MODE

12/22/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/500,207	Applicant(s) TAMURA ET AL.	
	Examiner SHARON WEN	Art Unit 1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 12 September 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-3, 5, 6, 9-11, 13-16 and 49-51 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 11 and 13-15 is/are allowed.
- 6) ☒ Claim(s) 1-3, 5-6, 9-10, 16 and 49-51 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after Final Rejection. Since this application is eligible for continued Examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office Action has been withdrawn pursuant to 37 CFR 1.114.

Applicant's submission filed on 09/12/2008 has been entered.

2. Applicant's amendments filed 09/12/2008 have been entered.

Claims 4, 7-8, 12 and 17-48 have been canceled.

Claims 1-3, 5-6, 9-11, 13-16 and 49-51 are pending and currently under examination as they read on a method of treating arthritis comprising administering an antibody which specifically binds to FGF-8.

Priority

3. The domestic priority date for claims 1-3, 5-6, 9-11, 13-16 and 49-51 is deemed the filing date of PCT/JP02/13650, i.e., 12/26/2002.

Applicant's claim for foreign priority is acknowledged. Certified copies of foreign priority application, 2001-400677, submitted under 35 U.S.C. 119(a)-(d), have been placed of record in the file. The support for Applicant's claim for foreign priority cannot be determined because application 2001-400677 is in Japanese and no certified translation has been provided

Applicant's amendment to the first line of the specification, filed 06/28/2004, for updating the priority claim is acknowledged and has been entered.

Specification

4. Applicant is invited to review the application for the spelling error, use of trademarks, embedded hyperlinks and/or other form of browser-executable code.

Art Unit: 1644

Trademarks should be capitalized wherever it appears and be accompanied by the generic terminology. Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks.

Embedded hyperlinks and/or other form of browser-executable code are impermissible in the text of the application as they represent an improper incorporation by reference.

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. Upon further consideration, the previous rejection under 35 USC 103(a) as being unpatentable over Baird et al. (U.S. Patent 6,037,329) in view of Hanai et al. (U.S. Patent 5,952,472) and Owen et al. (*Journal of Immunological Methods*, 1994, 168:149-165) has been withdrawn in view of Applicant's remarks, filed 09/12/2008.

7. Claims 1-3, 5-6, 9-10, 16 and 49-51 are rejected under 35 U.S.C. 103(a) as being unpatentable over Seddon et al. (U.S. Patent 5,491,220) in view of Hanai et al. (U.S. Patent 5,952,472) and Owen et al. (*Journal of Immunological Methods*, 1994, 168:149-165).

The instant claims are directed to a method of treating arthritis comprising administering an anti-FGF-8 antibody to inhibit activity of FGF-8, wherein the antibody is a monoclonal, humanized, i.e., human chimeric or human CDR-grafted, or a fragment thereof.

Seddon et al. teach a method of treating arthritis, in particular, rheumatoid arthritis, comprising administering an inhibitor of FGF (see entire document, in particular, see column 12, lines 42-49).

Seddon et al. did not teach using an antibody as the inhibitor of FGF to treat arthritis. However, antibodies to FGF, particularly anti-FGF-8 antibodies, as inhibitors of FGF, were well known in the art at the time of the invention was made as evidenced by Hanai et al. (see entire document).

Hanai et al. taught the same monoclonal antibody, KM 1334, as evidenced by the instant specification to recognize SEQ ID NO: 17 (see instant specification on page 132) wherein said monoclonal antibody neutralized the activity of FGF-8 (see entire document, in particular, see column 2, lines 9-10). In addition, Hanai et al. taught using the anti-FGF-8 monoclonal antibody which is produced from a hybridoma to treat diseases such as cancer where neovascularization plays a dominant role in the pathogenesis (see Background and Summary of the Invention in columns 1-2).

Although Seddon et al. also did not teach FGF-8 as the specific FGF to target for treating arthritis, given the finite known species of FGF, it would have been obvious to one of ordinary skill in the art to target FGF-8.

The rationale to support a conclusion that the claim would have been obvious is that a person of ordinary skill has good reason to pursue the known options (e.g. administration an anti-FGF-8 antibody for therapeutic purposes as taught by Hanai et al.) within his or her technical grasp. This leads to the anticipated success of treating arthritis with inhibitory anti-FGF-8 antibody. It is likely the product not of innovation but of ordinary skill and common sense.

Given the teachings of the two references, it is *prima facie* obvious to one of ordinary skill in the art, at the time of filing of the instant application, to substitute the anti-FGF-8 antibody as taught by Hanai et al. for the antagonist of FGF in the method of treating arthritis as taught by Seddon et al. for the same purpose of treating arthritis.

An ordinary artisan would have been motivated to use the anti-FGF-8 antibody to treat arthritis given the teaching by Seddon et al. stating FGF antagonists “that acts as angiogenesis inhibitor are useful for the treatment of diseases where neovascularization is dominant in the pathology such as...chronic inflammation, rheumatoid arthritis, and the like” (see column 12, lines 42-49) and the teaching by Hanai et al. in the anti-FGF-8 antibody having the neutralization activity specifically against FGF-8 would be effective in treating cancer wherein neovascularization is dominant in pathology (see column 1, third paragraph).

Even though the combined teachings of Seddon et al. and Hanai et al. were silent on “inhibiting joint destruction”, “protecting cartilage”, or “inhibiting growth of synovial membrane” (claims 49-51), given that the combined teachings rendered the claimed method of treating arthritis comprising administering an anti-FGF-8 antibody *prima facie* obvious, it does not appear that the claim language or limitations result in a manipulative difference in the method steps when compared to the prior art disclosure. Therefore, one of ordinary skill would recognize that the same method steps comprising administering the anti-FGF-8 antibody would also be able to inhibit joint destruction, protect cartilage or inhibit growth of synovial membrane.

Seddon et al. and Hanai et al. did not teach a humanized, i.e., human chimeric or human CDR-grafted antibody or the antigen binding fragments thereof. However, it is well known in the art, at the time of filing, to humanize antibodies or obtain the antigen-binding fragments thereof for therapeutic purposes in human as demonstrated by Owens et al. (see entire document).

In particular, Owens et al. taught the methods of making human chimeric antibodies and human CDR-grafted antibodies from rodent monoclonal antibodies (see pages 150-155). Moreover, Owens et al. taught the construction of antigen-binding fragments, in particular, F(ab')₂, Fab, Fv and scFV, which read on a “CDR-containing peptide” (claim 16) (see Owens et al., pages 155-157).

Art Unit: 1644

Given the combined teachings of Seddon et al. and Hanai et al., in view of Owens et al., it is *prima facie* obvious to one of ordinary skill in the art, at the time of filing of the instant application, to substitute the anti-FGF-8 antibody as taught by Hanai et al. for the FGF-8 antisense molecule in the method of treating arthritis as taught by Seddon et al. for the same purpose of treating arthritis, wherein the antibody is human chimeric, human CDR-grafted or antigen-binding fragments thereof as taught by Owens et al.

An ordinary artisan would have been motivated to humanize the antibody according to the methods taught by Owens et al. because Owens et al. teach a need for humanizing rodent monoclonal antibodies due to problems associated with using the rodent monoclonal antibodies in human therapy and advantages associated with using antigen binding fragments thereof, i.e., shorter half-lives in vivo (see Introduction on page 149).

Therefore, the invention, as a whole, was *prima facie* obvious to one of ordinary skill in the art, at the time the invention was made as evidenced by the references, especially in the absence of evidence to the contrary.

Conclusion

8. Claims 11 and 13-15 are allowed.

Claims 1-3, 5-6, 9-10, 16 and 49-51 are rejected.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHARON WEN whose telephone number is (571)270-3064. The examiner can normally be reached on Monday-Thursday, 8:30AM-6:00PM, ALT. Friday, EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eileen O'Hara can be reached on (571)272-0878. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1644

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Sharon Wen/

Examiner, Art Unit 1644

December 4, 2008

/Phillip Gambel/

Primary Examiner, Art Unit 1644